Summit Therapeutics PLC（SMMT）今日盘后股价大幅上涨5.03%，引起了市场的高度关注。
消息面上，此次股价上涨主要得益于公司与其中国合作伙伴Akeso共同开发的肺癌治疗药物ivonescimab在关键临床试验中取得了突破性成果。一项头对头研究结果显示，接受ivonescimab联合化疗的晚期鳞状非小细胞肺癌患者，其平均生存期达到27.9个月，比竞争对手BeOne Medicines的Tevimbra疗法（23.7个月）整整高出15%。这一积极数据在美国临床肿瘤学会（ASCO）年会上公布，显著增强了投资者对公司未来商业潜力的信心。
Ivonescimab是一种双特异性抗体药物，能同时阻断PD-1和VEGF蛋白，具有创新的治疗机制。Summit Therapeutics通过一项价值高达50亿美元的协议，获得了该药物在美国、加拿大、欧洲和日本的权益。分析人士指出，这一试验进展标志着公司在肿瘤治疗领域取得了重要突破，尽管其全球疗效仍需进一步验证，但当前的积极结果已足以推动市场情绪向好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.